BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript BTAI earnings call for the period ending March 31, 2020.

BTI's two most … Its principal clinical development programs are BXCL501 and BXCL701. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric … BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

Joins Company as Vice President, Oncology R&D .

He was also involved in the early development of the approved immuno-oncology agent, Bavencio (anti-PDL1), and discovered …

BioXcel Strengthens Leadership Team With Two Key Appointments. Responsibilities included strategic marketing, content marketing, thought leadership development and project execution with key cross-functional teams.

The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. About BioXcel Therapeutics, Inc.:BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. Equipped with excellent leadership skills and a cheerful disposition, he possesses an exceptional understanding of cross-functional drug development in both pre-clinical and clinical phases, always keeping the larger business objectives in mind. I endorse … The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates …

Prior to joining BioXcel Therapeutics, Richard served as Vice President and CFO at Remedy Pharmaceuticals, Inc., until it sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. Previously, he held multiple preclinical and clinical project leadership positions at Curagen, Sopherion Therapeutics, EMD Serono and Boston Strategics. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BRANFORD, Conn., June 16, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in …

Download as PDF June 16, 2015. Identified opportunities for global event participation and generation … BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a clinical stage biopharmaceutical company focused on two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer and pancreatic … Former AstraZeneca and BMS Executive Frank Yocca, Ph.D. Named Senior Vice President, CNS R&D; Former Merck Serono Executive Luca Rastelli, Ph.D. Sameer is a critical thinker with a bias for meaningful action and doesn't believe in half measures.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. He was Vice President for Oncology and Translational Sciences at BioXcel Therapeutics (NASDAQ: BTAI) until March 2018. … BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience Enhances company’s … He is the real deal, the one who walks the talk!

Prior to joining Remedy Pharmaceuticals, Mr. Steinhart served as an independent consultant to biotechnology and medical device companies.

Led global marketing for the company’s first-in-class artificial intelligence platform InveniAI and differentiated portfolio offerings Bioxcel Therapeutics across US, Europe and Japan.

"We couldn't be more pleased to welcome Reina to BTI, as her addition will significantly strengthen our leadership structure," commented Vimal Mehta, Ph.D., Chief Executive Officer… NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify …